Research
Hormonal
Combined supplementation with calcium and vitamin D significantly reduces hip and non-vertebral fracture rates in elderly women and men, primarily by correcting Vitamin D status and reducing serum PTH levels.
If you are elderly, ensure you are getting both Calcium and Vitamin D. Studies show that taking them together significantly reduces the risk of hip fractures, likely by improving calcium absorption and regulating hormones that protect bone.
GoodSupportsHIGH confidence
Studies of combined supplementation with Ca and vitamin D for 1.5– 3 years have shown impressive reductions in hip-fracture incidence in elderly women (mean age 84 years)... Correction of poor vitamin D status and reduction in serum PTH levels appear to be central to the mechanism of this effect.
Why this rating
Cites specific intervention trials showing impressive reductions in hip fractures.
Source
Calcium intake, calcium bioavailability and bone health
Cashman K.D.* · British Journal Of Nutrition · 2002
DOI 10.1079/bjnbjn/2002534
narrative_reviewCited 263×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic calcium deficiency resulting from inadequate intake or poor intestinal absorption causes reduced bone mass and osteoporosis by triggering parathyroid hormone (PTH)-mediated bone resorption.Good
- Non-digestible oligosaccharides (NDOs) such as inulin and oligofructose increase calcium absorption in adolescents and postmenopausal women, but not necessarily in healthy adult men.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →